A dermis-on-a-chip model for compound screening.

ABSTRACT: Dermal fibrosis is a significant barrier to effective wound healing, with excessive myofibroblast activation and extracellular matrix deposition leading to scar formation and compromised tissue function. Current in vitro models for studying dermal fibrosis, such as monolayer cultures and human skin equivalents (HSEs), have limited physiological relevance or scalability for drug screening. Here, we present a dermis-on-a-chip platform to enable screening of anti-fibrotic compounds in physiologically-relevant 3D dermal microtissues. Upon treatment with transforming growth factor beta (TGFβ), the tissues exhibited hallmarks of fibrosis, including impaired integrity, increased tensile forces, altered cellular morphology, and a pro-fibrotic cytokine profile. Conversely, incorporation of Q

SUBMITTER: Abdo D 

PROVIDER: S-EPMC12309271 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature